Skip to content

Term

Intermittent SSRI dosing: what it means

Intermittent dosing means taking an SSRI only during part of your cycle, usually the two weeks before your period, instead of every day. Trials show it works about as well as daily dosing for PMDD, with fewer total days of medication. A doctor decides if and when to try it.

Updated Niyora editorial

At a glance

  • Intermittent dosing means taking an SSRI only in the luteal phase, roughly from ovulation to your period, not every day.
  • A 2023 meta-analysis of 8 trials and 460 women found intermittent dosing works about as well as continuous dosing for premenstrual symptoms.
  • Response to intermittent SSRIs can begin within hours and peak within about 2 days, much faster than typical antidepressant timelines.
  • Some trials use symptom-onset dosing instead, starting the medication the day symptoms begin rather than on a fixed date.
  • A doctor decides which schedule fits your symptom pattern. This isn't something to adjust on your own.

What is intermittent dosing?

Intermittent dosing means taking an SSRI only during part of your cycle, not every day. For premenstrual dysphoric disorder (PMDD), that usually means starting the medication around ovulation and stopping once your period begins.

Doctors use four dosing schedules for PMDD:

  • Continuous dosing: the same dose every day, all month.
  • Intermittent dosing: starting around ovulation and stopping once your period begins, covering the luteal phase, when PMDD symptoms tend to build.
  • Symptom-onset dosing: starting the medication the day symptoms begin, rather than on a fixed calendar date (2015 trial [4]).
  • Semi-intermittent dosing: a low dose all month with a higher dose added during the luteal phase (1998 trial [7]).

A doctor who knows your symptom pattern decides which schedule, if any, fits your case.

How does it relate to PMS and PMDD?

PMDD is a different reaction to normal hormone changes, not abnormal hormone levels (Schmidt et al., 1998, NEJM; Dubey et al., 2017, Molecular Psychiatry). Estrogen and progesterone fall in the days before a period, and in PMDD, the brain responds to that fall with mood symptoms severe enough to disrupt daily life. See what causes PMDD for more on this mechanism.

Researchers have proposed two mechanisms for why intermittent dosing works:

  • Fluoxetine may slow the breakdown of estrogen late in the luteal phase by blocking an enzyme called CYP3A4, which may ease symptoms tied to hormone shifts (2025 review [6]).
  • Allopregnanolone, a hormone byproduct that affects some of the same brain receptors as alcohol and anti-anxiety medication, may also play a role.

Because PMDD symptoms come and go with the cycle, intermittent dosing only treats the window when they're present, instead of medicating every day of the month.

What does the research say?

Intermittent dosing has been tested against continuous dosing using fluoxetine, sertraline, citalopram and escitalopram.

In a small early trial, 75% of women responded to intermittent fluoxetine, close to the 67% response rate seen with continuous dosing (1997 trial [1]). A larger 2023 meta-analysis of 8 trials and 460 women found no significant difference between the two schedules in response, dropout or symptom change (2023 meta-analysis [3]).

Dosing schedule When it's taken What trials found
Continuous Every day, all cycle Effective, but carries a withdrawal risk if stopped (2023 meta-analysis [3])
Intermittent Ovulation through early bleeding As effective as continuous dosing across 460 women (2023 meta-analysis [3])
Symptom-onset Starting the day symptoms begin Reduced symptoms in a 252-woman trial (2015 trial [4])
Semi-intermittent Low dose all month, higher in luteal phase Less effective than full intermittent dosing (1998 trial [7])

Why does the dosing schedule matter?

Intermittent dosing matters because it offers an option with fewer total days of medication, which some women prefer. PMDD treatment guidelines list it alongside continuous dosing as a first-line SSRI option (2006 guideline [5]).

Trials show the two schedules work about equally well, so the choice often comes down to side effects, convenience and what your doctor recommends.

If you're deciding what to do with a hard moment before your period, rather than which medication schedule fits, Niyora is a PMS and PMDD support app. Its Moon feature helps you write down what happened, see it from another angle and draft a reply you can hold onto before you send it.

Related terms:

  • PMDD, explained: the full guide to diagnosis and treatment
  • corpus luteum: the structure whose breakdown triggers the hormone drop linked to PMDD
  • allopregnanolone: a progesterone byproduct thought to play a role in PMDD symptoms
  • luteal phase: the part of the cycle when intermittent dosing is typically used

From the research library

Research on SSRIs

528 studies in the library look at SSRIs in PMS and PMDD. They were published from 1971 to 2026, and each one has a short summary of what was tested and found.

528

studies, 1971 to 2026

How strong the studies are

Strong study design
102
Moderate study design
156
Early or limited evidence
270

See all 528 studies on SSRIs and antidepressants

Questions people ask

What does intermittent dosing mean for PMDD medication?+

Intermittent dosing means taking an SSRI only in the luteal phase, roughly from ovulation to the first days of your period, instead of every day. For PMS and PMDD, luteal-phase sertraline improved mood and physical symptom scores more than placebo over three cycles in a randomized trial of severe PMS (2004 trial [2]).

Is intermittent SSRI dosing as effective as continuous dosing?+

Intermittent SSRI dosing is about as effective as continuous dosing for premenstrual symptoms. A meta-analysis of 8 trials and 460 women found no significant difference in response rate, dropout rate or symptom change between the two schedules (2023 meta-analysis [3]).

How fast does intermittent dosing work for PMDD?+

Intermittent dosing for PMDD can work faster than daily SSRIs typically do for depression, which usually take weeks to help. This speed may relate to how SSRIs affect allopregnanolone, a hormone byproduct linked to mood.

What is symptom-onset dosing?+

Symptom-onset dosing means starting an SSRI the day PMDD symptoms begin, rather than on a fixed calendar date, and continuing through the first days of your period. A 252-woman trial found this approach reduced symptoms and improved functioning (2015 trial [4]).

Can intermittent dosing cause withdrawal symptoms?+

Intermittent dosing is often chosen specifically to reduce the risk of antidepressant withdrawal symptoms that can come with stopping continuous daily SSRIs (2023 meta-analysis [3]). An early trial also found intermittent dosing was mostly free of side effects for women with PMDD (1997 trial [1]).

Sources

  1. 1.Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria, Psychopharmacology bulletin, 1997
  2. 2.Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder, The American journal of psychiatry, 2004
  3. 3.Intermittent selective serotonin reuptake inhibitors for premenstrual syndromes: A systematic review and meta-analysis of randomised trials, Journal of psychopharmacology (Oxford, England), 2023
  4. 4.Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder: A Randomized Clinical Trial, JAMA psychiatry, 2015
  5. 5.Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs, Journal of women's health (2002), 2006
  6. 6.Mechanism of intermittent dosing of fluoxetine in premenstrual dysphoric disorder, Archives of women's mental health, 2025
  7. 7.Intermittent Selective Serotonin Reuptake Inhibitors for Premenstrual Syndromes: A Systematic Review and Meta-Analysis of Randomized Trials, 2022
  8. 8.Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle?, Journal of clinical psychopharmacology, 1998